Related Experiment Video

Updated: May 11, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

[Efficacy of iodine-131 in treating hyperthyroid heart disease]

Juan-Juan Song1, Yan-Song Lin, Li Zhu

  • 1Department of Nuclear Medicine, PUMC Hospital, CAMS and PUMC, Beijing, China.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
|May 7, 2013
PubMed

Insights

Iodine-131 therapy effectively treats hyperthyroid heart disease (HHD) in patients with Graves' disease or Plummer disease. This treatment achieved a 76% remission rate, normalizing thyroid hormone levels and improving cardiac function.

Area of Science:

  • Endocrinology
  • Cardiology
  • Nuclear Medicine

Context:

  • Hyperthyroid heart disease (HHD) is a serious complication of hyperthyroidism, often associated with Graves' disease or Plummer disease.
  • Cardiac manifestations, such as atrial fibrillation, are common in HHD and can lead to significant morbidity.

Purpose:

  • To evaluate the efficacy of iodine-131 therapy in managing hyperthyroidism in patients with HHD.
  • To assess the impact of iodine-131 treatment on thyroid hormone levels and cardiac complications.

Summary:

  • A study of 40 HHD patients (31 Graves', 9 Plummer) treated with iodine-131 showed significant reductions in serum free triiodothyronine, free thyroxine, and increases in thyroid-stimulating hormone.
  • The overall remission rate for hyperthyroidism was 76.0%, with notable improvements in thyroid hormone profiles post-treatment.
  • Atrial fibrillation was the most frequent cardiac complication, observed in 62.5% of patients.

Impact:

  • Iodine-131 therapy provides an effective and timely treatment option for controlling hyperthyroidism in HHD patients.
  • Successful management of hyperthyroidism through iodine-131 therapy can mitigate cardiac risks and improve patient outcomes.
Abstract

Related Concept Videos

Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...